Ссылки
1. Smith R. A ripping yarn of editorial misconduct. BMJ. Group blogs. 2008 Oct 21.
2. Smith R. The Trouble with Medical Journals. London: Royal Society of Medicine; 2006.
3. Schafer A. Biomedical conflicts of interest: a defence of the sequestration thesis – learning from the cases of Nancy Olivieri and David Healy. J Med Ethics. 2004; 30: 8–24.
4. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: writing and editing for biomedical publication. February 2006. International Committee of Medical Journal Editors website. Available online at: www.icmje.org (accessed 23 January 2006).
5. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med. 2005; 2: e138.
6. Smith R., Roberts I. Patient safety requires a new way to publish clinical trials. PLoS Clin Trials. 2006; 1(1): e6.
7. Wilkes M.S., Doblin B.H., Shapiro M.F. Pharmaceutical advertisements in leading medical journals: experts’ assessments. Ann Intern Med. 1992; 116: 912–19.
8. Lexchin J., Light D.W. Commercial infl uence and the content of medical journals. BMJ. 2006; 332: 1444–7.
9. Lundh A., Barbateskovic M., Hróbjartsson A., et al. Conflicts of interest at medical journals: the infl uence of industry-supported randomised trials on journal impact factors and revenue – cohort study. PLoS Med. 2010; 7: e1000354.
10. Drazen J.M., Curfman G.D. Financial associations of authors. N Engl J Med. 2002; 346: 1901–2.
11. Kassirer J. What the New England Journal of Medicine did. BMJ. 2011; 343: d5665.
12. Horton R. The dawn of McScience. New York Rev Books. 2004; 51: 7–9.
13. Eaton L. Editor claims drug companies have a ‘parasitic’ relationship with journals. BMJ. 2005; 330: 9.
14. Handel A.E., Patel S.V., Pakpoor J., et al. High reprint orders in medical journals and pharmaceutical industry funding: case-control study. BMJ. 2012; 344: e4212.
15. Hróbjartsson A., Gøtzsche P.C. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001; 344: 1594–602.
16. Jørgensen K.J., Johansen H.K., Gøtzsche P.C. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev. 2006; 1: CD004707.
17. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002; 346: 225–34.
18. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347: 408–15.
19. Jørgensen K.J., Johansen H.K., Gøtzsche P.C. Flaws in design, analysis and interpretation of Pfizer’s antifungal trials of voriconazole and uncritical subsequent quotations. Trials. 2006, 7: 3.
20. Johansen H.K., Gotzsche P.C. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999; 282: 1752–9.
21. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356: 775–89.
22. Suissa S., Ernst P., Vandemheen K.L., et al. Methodological issues in therapeutic trials of COPD. Eur Respir J. 2008; 31: 927–33.
23. Bero L.A., Galbraith A., Rennie D. The publication of sponsored symposiums in medical journals. N Engl J Med. 1992; 327: 1135–40.
24. Cho M.K., Bero L.A. The quality of drug studies published in symposium proceedings. Ann Intern Med. 1996; 124: 485–9.
25. Lenzer J. Editor earned over $20m in royalties and $2m in fees from device manufacturer. BMJ. 2010; 340: c495.
26. Carragee E.J., Hurwitz E.L., Weiner B.K. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011; 11: 471–91.
27. Abbasi K. Editor’s choice: a tough nut to crack. BMJ. 2005; 330: Jan 29.
28. Abramson J. Overdo$ed America: the broken promise of American medicine. New York: HarperCollins; 2004.
6. Легкие деньги развращают
Около 20 лет назад со мной произошла одна история, которая меня насторожила. Клинические исследователи из нескольких стран приняли участие в заседании по планированию, где обсуждались различные испытания, в которых могли быть заинтересованы и компания, и мы. Когда мы уже были на полпути в ресторан, где нас ждал роскошный обед, оплаченный компанией, сотрудник, ответственный за клинические испытания в компании, вручил мне конверт, который я открыл позже.
Конец ознакомительного фрагмента.
Текст предоставлен ООО «ЛитРес».
Прочитайте эту книгу целиком, купив полную легальную версию на ЛитРес.
Безопасно оплатить книгу можно банковской картой Visa, MasterCard, Maestro, со счета мобильного телефона, с платежного терминала, в салоне МТС или Связной, через PayPal, WebMoney, Яндекс.Деньги, QIWI Кошелек, бонусными картами или другим удобным Вам способом.